Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a ...

Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower.

Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 ...

Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...

Stroke drug developer Argenica Therapeutics plans a second trial to test its novel candidate, in a sector that has few ...

Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and ...

Okay, I thought Merck got, you know what, Merck reported a really good quarter, and it just happened on a day when people ...

Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.

Merck posted a narrower-than-expected loss and strong worldwide sales for the first quarter. (Marko Georgiev/) Merck reported ...

US pharma major Merck reported first-quarter revenue of $16.3 billion, up 5%, while posting a GAAP loss of $1.72 per share ...

Dow Jones Top Company Headlines at 7 AM ET: Blackstone Adds New Unit to Focus Its AI Momentum | Cigna ... Called BXN1, the new arm will concentrate some of the firm's AI bets as it also underscores ...